Atlas Venture Fund X L.P. 13D and 13G filings for Magenta Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-05-05 4:01 pm Sale |
2021-04-13 | 13D | Magenta Therapeutics, Inc. MGTA |
Atlas Venture Fund X L.P. | 2,977,448 5.100% |
-379,892 (-11.32%) |
Filing |
| 2021-02-17 08:26 am Sale |
2021-02-11 | 13D | Magenta Therapeutics, Inc. MGTA |
Atlas Venture Fund X L.P. | 3,357,340 7.000% |
-759,785 (-18.45%) |
Filing |
| 2020-07-14 4:34 pm Unchanged |
2020-06-29 | 13D | Magenta Therapeutics, Inc. MGTA |
Atlas Venture Fund X L.P. | 4,117,125 8.700% |
0 (Unchanged) |
Filing |